Salta alla navigazione principale
Salta alla ricerca
Salta al contenuto principale
Ordina per
Keyphrases
ERRFI1
100%
Adaptive Resistance
100%
MiR-205
100%
MET Inhibition
100%
EGFR Signaling
100%
MET Tyrosine Kinase Inhibitor
57%
EGFR Transactivation
28%
Secondary Resistance
28%
Rational Design
14%
Cancer Cell Lines
14%
In Cancer
14%
Clinical Significance
14%
Deregulation
14%
Overexpression
14%
Therapeutic Strategies
14%
Cancer Patients
14%
Genetic Modification
14%
Targeted Therapy
14%
Resistant Cells
14%
Lung Adenocarcinoma
14%
Long-term Efficacy
14%
Inhibitor-1
14%
Tyrosine Kinase Inhibitor Treatment
14%
RNA Sequencing (RNA-seq)
14%
Clinical Resistance
14%
Inhibitor Resistant
14%
Crizotinib Resistance
14%
ErbB Receptors
14%
MiRNA Profiling
14%
EGFR Inhibition
14%
Anti-miR
14%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
microRNA 205
100%
Protein Tyrosine Kinase Inhibitor
71%
Malignant Neoplasm
28%
Receptor
14%
Lung Adenocarcinoma
14%
Crizotinib
14%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Tyrosine Kinase Inhibitor
100%
Downregulation
20%
Gene Mutation
20%
Mediator
20%
Cancer Cell
20%
RNA Sequencing
20%
Crizotinib
20%
Immunology and Microbiology
Tyrosine
100%
Downregulation
20%
Mediator
20%
Cancer Cell Line
20%
Gene Mutation
20%
RNA Sequencing
20%
Crizotinib
20%